[AstraZeneca United States](https://www.astrazeneca-us.com)

Rolling (applications reviewed on a rolling basis)

No fixed amount; varies by project and therapeutic area, subject to available budget.

Supports non-promotional educational and scientific initiatives across multiple therapeutic areas for researchers, clinicians, and students.

Programs must be educational, non-promotional, and adhere to FDA guidance on industry-supported activities.

--- ## Description AstraZeneca United States offers grant funding for a broad range of educational initiatives and scientific activities. These grants are designed to inform and educate researchers, healthcare professionals, and students across numerous therapeutic areas, including but not limited to cardiovascular, infections and vaccines, nephrology, neurology, oncology (various cancer types), respiratory, rheumatology, immunology, autoimmune disorders, and scientific research and development. All supported programs must be strictly educational and non-promotional, in compliance with U.S. Food and Drug Administration (FDA) guidance. Programs may include live or virtual events, enduring educational materials, podcasts, panel discussions, simulations, patient case studies, and print materials. Proposals should address unmet educational needs and may target a variety of healthcare professionals and scientific audiences. --- ## Due Dates - Applications are accepted and reviewed on a rolling basis; there is no set deadline. - For specific requests for proposals (RFPs), such as those in transthyretin amyloidosis, anticipated program start dates may range from February 1, 2026, through December 31, 2026, but the application review remains rolling. --- ## Funding Amount - No fixed award amount; funding is determined based on the scope, scale, and educational value of the proposed initiative. - Some areas may have a limited budget; applicants are encouraged to contact AstraZeneca in advance for guidance on budget availability, especially in areas such as asthma, EGPA, HES, SLE, and severe viral LRTD. --- ## Eligibility - Eligible applicants include educational providers, academic institutions, scientific and professional organizations, healthcare institutions, and non-profit entities. - Programs must be strictly educational and non-promotional. - Activities must be planned, designed, and implemented in accordance with FDA guidance on industry-supported scientific and educational activities. - Specific eligibility or focus may apply to certain therapeutic areas or RFPs; review the relevant call for details. --- ## Application Process - Review the [Areas of Educational Interest](https://www.astrazeneca-us.com/sustainability/Request-Support/medical-education-office/educational-areas-call-for-grants.html) to ensure alignment with AstraZeneca’s priorities. - Prepare a formal letter of request and a detailed grant proposal, including: - Needs assessment - Learning objectives - Program agenda - Budget proposal - Submit applications through the designated portal or, for some areas, by emailing [grants@astrazeneca.com](mailto:grants@astrazeneca.com). - For specific RFPs (e.g., ATTRv Amyloidosis), refer to the linked PDF or contact the relevant AstraZeneca staff listed in the RFP. --- ## Additional Information - Some therapeutic areas may have a limited budget or specific requirements (e.g., a concept email is required before submitting a full application). - U.S. Federal Sunshine Act (Open Payments) reporting requirements apply to grants and transfers of value to physicians and teaching hospitals. - Non-U.S. applicants should review area-specific eligibility, as some topics are restricted to non-U.S. programs. --- ## External Links - [AstraZeneca US Medical Education & Scientific Sponsorships](https://www.astrazeneca-us.com/sustainability/Request-Support/medical-education-office.html) - [Educational Areas / Call for Grants Program Page](https://www.astrazeneca-us.com/sustainability/Request-Support/medical-education-office/educational-areas-call-for-grants.html) - [Example RFP: ATTRv Amyloidosis (PDF)](https://www.astrazeneca-us.com/content/dam/az-us/Sustainability/PDF/CGA-Amyloidosis-2026.pdf) - [Grant Reporting and Open Payments](https://www.astrazeneca-us.com/sustainability/Request-Support/medical-education-office/grant-reporting.html) - [AstraZeneca Ethics and Transparency](https://www.astrazeneca.com/sustainability/ethics-and-transparency/astrazeneca-and-global-transparency.html) --- ## Contact Information | Name/Role | Email | Phone | Web Link | |-----------------------------------------------|---------------------------------------------|---------------|----------------------------------------------------------------------------------------------| | Medical Education Grants Office (General) | [grants@astrazeneca.com](mailto:grants@astrazeneca.com) | 800-456-3669 | [Contact Us](https://www.astrazeneca-us.com/sustainability/Request-Support/medical-education-office/contact-us.html) | | Donna Maier, PhD (RFP-specific contact) | [donna.maier@astrazeneca.com](mailto:donna.maier@astrazeneca.com) | | | | US Media Team | [USMediateam@astrazeneca.com](mailto:USMediateam@astrazeneca.com) | | |

Educational Areas/Call for Grants

Sign in to see full grant listing